Foundry Healthcare Net Operating Assets Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1MCK | MCKESSON CORP | Healthcare | $101.14B | 24.28% |
2COR | CENCORA INC | Healthcare | $59.91B | 14.38% |
3CAH | CARDINAL HEALTH INC | Healthcare | $53.52B | 12.85% |
4CNC | CENTENE CORP | Healthcare | $32.81B | 7.87% |
5BBIO | BRIDGEBIO PHARMA INC | Healthcare | $15.94B | 3.83% |
6MEDP | MEDPACE HOLDINGS INC | Healthcare | $15.36B | 3.69% |
7AXSM | AXSOME THERAPEUTICS INC | Healthcare | $11.84B | 2.84% |
8MOH | MOLINA HEALTHCARE INC | Healthcare | $11.74B | 2.82% |
9OSCR | OSCAR HEALTH INC | Healthcare | $8.77B | 2.11% |
10IMVT | IMMUNOVANT INC | Healthcare | $8.27B | 1.98% |
11IBRX | IMMUNITYBIO INC | Healthcare | $8.04B | 1.93% |
12RYTM | RHYTHM PHARMACEUTICALS INC | Healthcare | $7.31B | 1.75% |
13HNGE | HINGE HEALTH INC | Healthcare | $6.74B | 1.62% |
14PTCT | PTC THERAPEUTICS INC | Healthcare | $6.52B | 1.56% |
15SRRK | SCHOLAR ROCK HOLDING CORP | Healthcare | $6.33B | 1.52% |
16DFTX | DEFINIUM THERAPEUTICS INC | Healthcare | $4.83B | 1.16% |
17ALHC | ALIGNMENT HEALTHCARE INC | Healthcare | $4.26B | 1.02% |
18IMNM | IMMUNOME INC | Healthcare | $2.53B | 0.61% |
19SLS | SELLAS LIFE SCIENCES GROUP INC | Healthcare | $2.45B | 0.59% |
20AGL | AGILON HEALTH INC | Healthcare | $2.17B | 0.52% |
21PLSE | PULSE BIOSCIENCES INC | Healthcare | $1.98B | 0.48% |
22AMLX | AMYLYX PHARMACEUTICALS INC | Healthcare | $1.97B | 0.47% |
23OCUL | OCULAR THERAPEUTIX INC | Healthcare | $1.96B | 0.47% |
24URGN | UROGEN PHARMA LTD | Healthcare | $1.96B | 0.47% |
25DMRA | DAMORA THERAPEUTICS INC | Healthcare | $1.94B | 0.47% |
26BFLY | BUTTERFLY NETWORK INC | Healthcare | $1.73B | 0.42% |
27TSHA | TAYSHA GENE THERAPIES INC | Healthcare | $1.71B | 0.41% |
28ANAB | ANAPTYSBIO INC | Healthcare | $1.69B | 0.41% |
29CMPS | COMPASS PATHWAYS PLC | Healthcare | $1.67B | 0.40% |
30MLTX | MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | $1.45B | 0.35% |
31OMDA | OMADA HEALTH INC | Healthcare | $1.41B | 0.34% |
32NVAX | NOVAVAX INC | Healthcare | $1.35B | 0.32% |
33INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.28B | 0.31% |
34MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $1.15B | 0.28% |
35SDGR | SCHRODINGER INC | Healthcare | $1.14B | 0.27% |
36WVE | WAVE LIFE SCIENCES LTD | Healthcare | $1.12B | 0.27% |
37FBRX | FORTE BIOSCIENCES INC | Healthcare | $1.00B | 0.24% |
38VOR | VOR BIOPHARMA INC | Healthcare | $980M | 0.24% |
39ANRO | ALTO NEUROSCIENCE INC | Healthcare | $967M | 0.23% |
40KURA | KURA ONCOLOGY INC | Healthcare | $964M | 0.23% |
41ANNX | ANNEXON INC | Healthcare | $950M | 0.23% |
42TBPH | THERAVANCE BIOPHARMA INC | Healthcare | $873M | 0.21% |
43PHAT | PHATHOM PHARMACEUTICALS INC | Healthcare | $873M | 0.21% |
44REPL | REPLIMUNE GROUP INC | Healthcare | $859M | 0.21% |
45AVR | ANTERIS TECHNOLOGIES GLOBAL CORP | Healthcare | $823M | 0.20% |
46CADL | CANDEL THERAPEUTICS INC | Healthcare | $746M | 0.18% |
47ACHV | ACHIEVE LIFE SCIENCES INC | Healthcare | $644M | 0.15% |
48TECX | TECTONIC THERAPEUTIC INC | Healthcare | $615M | 0.15% |
49STTK | SHATTUCK LABS INC | Healthcare | $577M | 0.14% |
50VSTM | VERASTEM INC | Healthcare | $530M | 0.13% |
51ZURA | ZURA BIO LTD | Healthcare | $518M | 0.12% |
52NVCT | NUVECTIS PHARMA INC | Healthcare | $508M | 0.12% |
53PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $453M | 0.11% |
54BNTC | BENITEC BIOPHARMA INC | Healthcare | $439M | 0.11% |
55TENX | TENAX THERAPEUTICS INC | Healthcare | $420M | 0.10% |
56CBIO | CRESCENT BIOPHARMA INC | Healthcare | $407M | 0.10% |
57STRO | SUTRO BIOPHARMA INC | Healthcare | $391M | 0.09% |
58FENC | FENNEC PHARMACEUTICALS INC | Healthcare | $365M | 0.09% |
59CV | CAPSOVISION INC | Healthcare | $335M | 0.08% |
60FHTX | FOGHORN THERAPEUTICS INC | Healthcare | $305M | 0.07% |
61SGHT | SIGHT SCIENCES INC | Healthcare | $274M | 0.07% |
62QTTB | Q32 BIO INC | Healthcare | $255M | 0.06% |
63SRZN | SURROZEN INC | Healthcare | $255M | 0.06% |
64RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $243M | 0.06% |
65GLSI | GREENWICH LIFESCIENCES INC | Healthcare | $240M | 0.06% |
66KPTI | KARYOPHARM THERAPEUTICS INC | Healthcare | $216M | 0.05% |
67KROS | KEROS THERAPEUTICS INC | Healthcare | $211M | 0.05% |
68AGEN | AGENUS INC | Healthcare | $209M | 0.05% |
69IMUX | IMMUNIC INC | Healthcare | $207M | 0.05% |
70DTIL | PRECISION BIOSCIENCES INC | Healthcare | $203M | 0.05% |
71AMWL | AMERICAN WELL CORP | Healthcare | $199M | 0.05% |
72TNXP | TONIX PHARMACEUTICALS HOLDING CORP | Healthcare | $198M | 0.05% |
73ACOG | ALPHA COGNITION INC | Healthcare | $185M | 0.04% |
74ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $172M | 0.04% |
75OWLT | OWLET INC | Healthcare | $162M | 0.04% |
76RCEL | AVITA MEDICAL INC | Healthcare | $157M | 0.04% |
77UNCY | UNICYCIVE THERAPEUTICS INC | Healthcare | $144M | 0.03% |
78PMN | PROMIS NEUROSCIENCES INC | Healthcare | $136M | 0.03% |
79VTVT | VTV THERAPEUTICS INC | Healthcare | $130M | 0.03% |
80AARD | AARDVARK THERAPEUTICS INC | Healthcare | $128M | 0.03% |
81JYNT | JOINT CORP | Healthcare | $127M | 0.03% |
82SPRB | SPRUCE BIOSCIENCES INC | Healthcare | $120M | 0.03% |
83VRCA | VERRICA PHARMACEUTICALS INC | Healthcare | $96M | 0.02% |
84RLYB | RALLYBIO CORP | Healthcare | $87M | 0.02% |
85CSBR | CHAMPIONS ONCOLOGY INC | Healthcare | $85M | 0.02% |
86NRXS | NEURAXIS INC | Healthcare | $84M | 0.02% |
87PIII | P3 HEALTH PARTNERS INC | Healthcare | $78M | 0.02% |
88ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $76M | 0.02% |
89CLNN | CLENE INC | Healthcare | $76M | 0.02% |
90SCLX | SCILEX HOLDING CO | Healthcare | $72M | 0.02% |
91LNSR | LENSAR INC | Healthcare | $70M | 0.02% |
92EDSA | EDESA BIOTECH INC | Healthcare | $59M | 0.01% |
93INKT | MINK THERAPEUTICS INC | Healthcare | $53M | 0.01% |
94XLO | XILIO THERAPEUTICS INC | Healthcare | $53M | 0.01% |
95EXOZ | EXOZYMES INC | Healthcare | $51M | 0.01% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $416.64B. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 92% toward Large, 37% toward Growth. +10% unclassified (20 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 95 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual60.6%Margin-14.4%No more than 25% of total assets may be invested in the securities of any one issuer.
Required<= 25.0%Actual24.3%Margin0.7%Close to the line. The engine flags this verdict as one a routine data rebuild could flip. Read it as borderline rather than settled — the margin beside it is the whole story.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
1 verdict(s) sit within 1.0pp of their limit and can be flipped by a routine data rebuild; do not headline them, and always show the margin.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 21%; both still land on the same side of the 2x limit.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 37.0% | 18.8% |
| 3 yearsp.a. | 19.1% | 10.8% |
| 5 yearsp.a. | 10.1% | 12.1% |
| 10 yearsp.a. | 14.0% | 8.3% |
| Since inceptionp.a. | 10.5% | 3.3% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 7.8% | 3.7% |
| 2025 | 43.2% | 34.2% |
| 2024 | 0.2% | -11.5% |
| 2023 | 20.9% | 15.4% |
| 2022 | -8.1% | 21.4% |
| 2021 | 23.4% | 27.5% |
| 2020 | 32.5% | 7.4% |
| 2019 | 22.6% | -5.2% |
| 2018 | -11.2% | -10.4% |
| 2017 | 34.3% | 14.4% |
| 2016 | -16.7% | -4.1% |
| 2015 | 7.8% | 6.0% |
| 2014 | 25.6% | -7.2% |
| 2013 | 47.9% | -3.3% |
| 2012 | 15.6% | -6.4% |
| 2011 | 16.4% | 14.5% |
| 2010 | 18.0% | 17.1% |
| 2009 | 31.9% | 10.9% |
| 2008 | -41.2% | -8.5% |
| 2007 | 16.6% | 5.7% |
| 2006 | 10.0% | 2.7% |
| 2005 | 21.3% | 17.0% |
| 2004 | 3.9% | 3.1% |
| 2003 | 54.4% | 13.6% |
| 2002 | -19.6% | 8.1% |
| 2001 | -14.0% | -7.3% |
| 2000 | 29.6% | -16.8% |
| 1999 | -17.0% | -27.1% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare Net Operating Assets Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Net Operating Assets signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.